{
  "thread": {
    "uuid": "88ca2af61921e401a35a2ff9ccf1c909a3a1614e",
    "url": "https://news.xmnn.cn/gnxw/202506/t20250619_349188.html",
    "site_full": "news.xmnn.cn",
    "site": "xmnn.cn",
    "site_section": "https://news.xmnn.cn/gnxw",
    "site_categories": [],
    "section_title": "\n    国内新闻_厦门网\n  ",
    "site_title": "厦门网_厦门市官方新闻门户网站",
    "title": "涨价282倍被罚3.55亿元，哄抬药价就该\"稳准狠\"打击 _新闻频道_厦门网",
    "title_full": "涨价282倍被罚3.55亿元，哄抬药价就该\"稳准狠\"打击 _新闻频道_厦门网",
    "published": "2025-06-19T07:37:32.166+03:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 47204,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "88ca2af61921e401a35a2ff9ccf1c909a3a1614e",
  "url": "https://news.xmnn.cn/gnxw/202506/t20250619_349188.html",
  "ord_in_thread": 0,
  "author": null,
  "published": "2025-06-19T07:37:32.166+03:00",
  "title": "涨价282倍被罚3.55亿元，哄抬药价就该\"稳准狠\"打击 _新闻频道_厦门网",
  "text": "6月13日，国家市场监督管理总局发布了关于地塞米松磷酸钠原料药垄断协议案行政处罚决定书。处罚决定书显示，四家企业因达成并实施地塞米松磷酸钠原料药价格垄断协议，最终被罚没款合计3.55亿元，此外组织者郭某某个人被顶格罚款500万元，四家药企的4名责任人各被罚60万元。据公开信息，上述药品价格曾从0.35元/支暴涨至98.76元/支，涨幅高达282倍。（见6月16日《中国新闻周刊》）\n地塞米松磷酸钠是一种原料药，被广泛用于抗炎、抗过敏、免疫抑制等用途。上述罚单背后的细节令人震惊，四家药企因垄断地塞米松磷酸钠原料药价格，导致该药品价格从0.35元/支暴涨至98.76元/支，涨幅高达282倍。这意味着许多患者因药价飞涨而增加了经济负担，医保基金也可能为此遭受一定损失。\n药品是守护生命安全的一道重要屏障，却被个别药企异化为“吸血的利刃”，折射出三大困境。首先，法律威慑力不足。反垄断法对药品垄断的处罚上限为企业销售额的10%，远低于其攫取的暴利。其次，受害者救济机制缺位。高价购药的患者、额外支出的医保部门都难以追回损失。此外，刑事责任追究存在模糊地带。垄断行为导致的间接健康损害很难被纳入刑责范围，法律制裁呈现一定的“软肋”。\n破解医药价格不合理“狂飙”现象，需构建立体化惩戒防御体系。立法层面，完善反垄断领域的法规法条，增设类似“民生必需品垄断加重处罚”的条款，将罚款比例进一步提升，并考虑引入“行业禁入”制度，加大对蠢蠢欲动者的震慑力度。执法层面，对导致老百姓产生健康损害等行为，要形成司法高压。行业治理层面，建立完善原料药动态监测平台，压缩少数企业垄断供应链并进行“暗箱操作”的可能性等。\n值得警惕的是，此次事件并非孤例。涉事企业之一在近年来因涉嫌垄断等原因已被连续处罚多次。此外，从醋酸氟轻松到卡莫司汀，原料药垄断案频发，暴露行业存在诸多漏洞。唯有将法律威慑、技术监管与行业重构相结合，下力气斩断操控药品定价的黑手，才能保障“救命药”回归治病救人的本质。\n遏制哄抬药价，是一场关乎生命安全的战役。以法律为剑、监管为盾，构建多方联动的治理网络，最大限度阻止“救命药”沦为“要命药”——这不仅是对市场规则的捍卫，更是对生命伦理的守护。 （舒爱民）\n责任编辑： 李伊琳,赖旭华",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance",
    "Politics",
    "Social Issue"
  ],
  "topics": [
    "Economy, Business and Finance->healthcare industry",
    "Economy, Business and Finance->financial and economic news",
    "Economy, Business and Finance->business governance",
    "Politics->economic policy",
    "Politics->regulation of industry",
    "Politics->government",
    "Social Issue->social problem",
    "Social Issue->social services",
    "Social Issue->social condition"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null
  },
  "rating": null,
  "crawled": "2025-06-19T07:37:32.166+03:00",
  "updated": "2025-06-19T04:39:44.000+00:00"
}